2016

Welcome to Grünenthal's Press Center

16 Dec 2016

Grünenthal receives Breakthrough Therapy Designation from U.S. FDA for neridronic acid for the treatment of complex regional pain syndrome (CRPS), a debilitating orphan disease with high medical need

Aachen, Germany, and Pisa, Italy – 16 December 2016 – Grünenthal, an R&D-driven, privately held international pharmaceutical company with headquarters in Germany, and Abiogen Pharma, privately held Italian pharmaceutical company with headquarter in Pisa, Italy announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to neridronic acid, an investigational medicine, for the treatment of complex regional pain syndrome (CRPS), a serious, disabling orphan disease. Today, with no FDA- or EMA-approved drug treatments, there is a clear need for effective treatment options to address this significant unmet medical need. CRPS is a debilitating condition characterized by severe, continuous, burning pain often occurring in an extremity after injury or surgery. It is one of the most painful conditions a patient can experience1.

More ...

16 Nov 2016

Grünenthal has acquired US-based Thar Pharmaceuticals Inc. to expand its development portfolio of treatment options for CRPS (Complex Regional Pain Syndrome), a serious, disabling orphan disease.

Aachen, Germany, and Pittsburgh, PA, USA – 16 November 2016 – Grünenthal, an R&D-driven, privately held international pharmaceutical company with headquarters in Germany, has announced its recent acquisition of Thar Pharmaceuticals, a US-based clinical-stage, specialty pharmaceutical company. Thar Pharmaceuticals focused on transforming IV-only drugs into oral drugs for existing and new indications using its proprietary technology EnhanceTM development platform. With this acquisition, Grünenthal has obtained the worldwide development and commercialization rights for Thar Pharmaceutical’s lead development candidate, T121.

More ...

04 Oct 2016

Gabriel Baertschi takes office as new CEO of Grünenthal Group
as of October 1, 2016

The Grünenthal Group today announces that Gabriel Baertschi has taken office as new CEO of the Grünenthal Group, an independent, family-owned, international research-based pharmaceutical company headquartered in Aachen, Germany. The company’s Supervisory Board had named Gabriel Baertschi to become Grünenthal’s new CEO in June 2016. Gabriel Baertschi is joining Grünenthal from AstraZeneca, a global, science-led biopharmaceutical business where in his last appointment he served as country president for Japan. He succeeds Prof. Dr. Eric-Paul Pâques who retires at the end of 2016 after 23 years at Grünenthal.

More ...

22 Feb 2016

PATHEON SELECTED BY GRÜNENTHAL TO DEVELOP DRUGS USING INTAC® ABUSE DETERRENT FORMULATIONS TECHNOLOGY

Patheon, the leading global provider of pharmaceutical development and manufacturing services today announced it has signed a strategic agreement with Grünenthal, an independent, family-owned, international research-based pharmaceutical group headquartered in Aachen, Germany to serve as its preferred development partner for its products made using Grünenthal’s innovative abuse deterrent formulation technology INTAC®.

More ...

08 Jan 2016

Grünenthal and Akashi Therapeutics Inc. announce joint drug development program for HT-100 in the treatment of patients with Duchenne Muscular Dystrophy (DMD)

  • HT-100 is an orally available small molecule drug candidate designed to reduce fibrosis and inflammation and to promote healthy muscle fiber regeneration in patients with DMD
  • DMD is a rare, yet the most common fatal genetic disorder diagnosed in childhood. Today, no curative treatment exists, and patients typically die in their twenties

More ...